Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Int J Antimicrob Agents. 2020 Jun;55(6):105995. doi: 10.1016/j.ijantimicag.2020.105995. Epub 2020 Apr 24.
Coronavirus disease 2019 (COVID-19) caused by the previously unknown pathogen, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) is now a global pandemic. There are no vaccines or specific treatments against this new virus; therefore, there is an urgent need to advance novel therapeutic interventions for COVID-19. Glycyrrhizin is a triterpene saponin with various biological functions and pharmacological effects. This brief article discusses the therapeutic potential of glycyrrhizin for the treatment of COVID-19 from the perspective of its pharmacological action, including binding angiotensin-converting enzyme II (ACE2), downregulating proinflammatory cytokines, inhibiting the accumulation of intracellular reactive oxygen species (ROS), inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon.
由先前未知的病原体——严重急性呼吸综合征相关冠状病毒-2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）现已在全球范围内流行。目前尚无针对这种新型病毒的疫苗或特效治疗方法；因此，迫切需要为 COVID-19 推进新的治疗干预措施。甘草酸是一种具有多种生物学功能和药理作用的三萜皂苷。本文从甘草酸的药理作用角度，探讨了甘草酸治疗 COVID-19 的潜在治疗作用，包括结合血管紧张素转化酶 II（ACE2）、下调促炎细胞因子、抑制细胞内活性氧（ROS）的积累、抑制凝血酶、抑制气道渗出物的过度产生以及诱导内源性干扰素。
